JNJ-78934804 Shows Efficacy in Crohn's Disease Compared to Guselkumab
A study is underway to evaluate the efficacy and safety of JNJ-78934804 against guselkumab in Crohn's disease patients at Week 48.
Indication
Clinical and regulatory intelligence for Crohn's Disease with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.